Primary |
Hepatic Neoplasm Malignant |
30.5% |
Renal Cell Carcinoma |
11.5% |
Drug Use For Unknown Indication |
10.8% |
Hypertension |
7.2% |
Renal Cell Carcinoma Stage Iv |
5.8% |
Prophylaxis |
5.8% |
Renal Cell Carcinoma Stage Unspecified |
5.4% |
Hepatocellular Carcinoma |
3.4% |
Metastatic Renal Cell Carcinoma |
3.0% |
Pain |
2.4% |
Diabetes Mellitus |
1.9% |
Constipation |
1.8% |
Hepatic Cancer |
1.7% |
Product Used For Unknown Indication |
1.5% |
Insomnia |
1.5% |
Gastritis Prophylaxis |
1.3% |
Renal Cancer |
1.3% |
Thyroid Cancer |
1.1% |
Diarrhoea |
1.0% |
Hepatic Cirrhosis |
0.9% |
|
Palmar-plantar Erythrodysaesthesia Syndrome |
16.1% |
Rash |
12.3% |
Weight Decreased |
7.0% |
Vomiting |
6.7% |
Pyrexia |
6.5% |
Death |
5.6% |
Stomatitis |
5.2% |
Hepatic Function Abnormal |
5.0% |
Diarrhoea |
4.3% |
Hepatic Encephalopathy |
4.1% |
Platelet Count Decreased |
3.7% |
Hepatic Neoplasm Malignant |
3.0% |
Renal Cell Carcinoma |
2.9% |
Hypertension |
2.9% |
White Blood Cell Count Decreased |
2.7% |
Hepatic Failure |
2.7% |
Nausea |
2.6% |
Rash Generalised |
2.3% |
Pain In Extremity |
2.2% |
Fatigue |
2.1% |
|
Secondary |
Hepatic Neoplasm Malignant |
24.3% |
Renal Cell Carcinoma |
13.4% |
Prophylaxis |
9.2% |
Hypertension |
8.3% |
Renal Cell Carcinoma Stage Iv |
7.6% |
Hepatocellular Carcinoma |
5.4% |
Drug Use For Unknown Indication |
4.6% |
Pain |
4.6% |
Constipation |
3.1% |
Hepatic Cancer |
2.8% |
Insomnia |
2.4% |
Metastatic Renal Cell Carcinoma |
2.0% |
Diabetes Mellitus |
1.9% |
Nausea |
1.8% |
Gastritis Prophylaxis |
1.7% |
Renal Cell Carcinoma Stage Unspecified |
1.6% |
Product Used For Unknown Indication |
1.5% |
Prophylaxis Against Gastrointestinal Ulcer |
1.4% |
Diarrhoea |
1.3% |
Thyroid Cancer |
1.2% |
|
Palmar-plantar Erythrodysaesthesia Syndrome |
22.6% |
Rash |
10.4% |
Vomiting |
7.7% |
Weight Decreased |
7.6% |
Pyrexia |
7.2% |
Stomatitis |
7.1% |
White Blood Cell Count Decreased |
5.6% |
Hepatic Function Abnormal |
4.8% |
Platelet Count Decreased |
4.7% |
Diarrhoea |
2.9% |
Renal Cell Carcinoma |
2.4% |
Hepatic Encephalopathy |
2.4% |
Malaise |
2.2% |
Nausea |
2.2% |
Hypertension |
1.9% |
Hepatic Neoplasm Malignant |
1.9% |
Skin Exfoliation |
1.7% |
Thrombocytopenia |
1.7% |
Pancreatic Enzymes Increased |
1.5% |
Pleural Effusion |
1.5% |
|
Concomitant |
Metastatic Renal Cell Carcinoma |
24.9% |
Metastases To Bone |
7.9% |
Product Used For Unknown Indication |
7.9% |
Nuclear Magnetic Resonance Imaging |
7.3% |
Pain |
5.0% |
Prophylaxis |
4.8% |
Cancer Pain |
4.6% |
Drug Use For Unknown Indication |
4.4% |
Liver Transplant |
4.0% |
Neoplasm Malignant |
3.7% |
Renal Cancer |
3.7% |
Renal Cell Carcinoma |
3.7% |
Hepatic Neoplasm Malignant |
3.3% |
Hypertension |
2.5% |
Neoplasm |
2.3% |
Constipation |
2.1% |
Hepatitis B |
2.1% |
Pulmonary Arterial Hypertension |
2.1% |
Diabetes Mellitus |
1.9% |
Nausea |
1.9% |
|
Death |
13.5% |
Skin Fibrosis |
8.3% |
Pain |
7.3% |
Wound Dehiscence |
7.3% |
Disease Progression |
6.3% |
Neoplasm Malignant |
5.2% |
Visual Acuity Reduced |
5.2% |
Weight Decreased |
5.2% |
Diarrhoea |
4.2% |
Rash |
4.2% |
Sepsis |
4.2% |
Toxic Epidermal Necrolysis |
4.2% |
Constipation |
3.1% |
Dermatitis Bullous |
3.1% |
Hyperkalaemia |
3.1% |
Joint Swelling |
3.1% |
Neoplasm Progression |
3.1% |
Off Label Use |
3.1% |
Pain In Jaw |
3.1% |
Pulmonary Fibrosis |
3.1% |
|
Interacting |
Hiv Infection |
30.4% |
Tuberculosis |
24.3% |
Hepatic Neoplasm Malignant |
14.2% |
Prophylaxis Against Gastrointestinal Ulcer |
8.1% |
Renal Cell Carcinoma Stage Iv |
8.1% |
Product Used For Unknown Indication |
3.4% |
Renal Cell Carcinoma |
3.4% |
Atrial Fibrillation |
1.4% |
Hepatitis B |
1.4% |
Hepatocellular Carcinoma |
1.4% |
Carcinoid Tumour Of The Gastrointestinal Tract |
0.7% |
Chronic Myeloid Leukaemia |
0.7% |
Hepatic Cancer |
0.7% |
Metastases To Bone |
0.7% |
Palliative Care |
0.7% |
Type 2 Diabetes Mellitus |
0.7% |
|
Tuberculosis |
36.4% |
Blister |
27.3% |
Tongue Discolouration |
9.1% |
Therapeutic Agent Toxicity |
6.1% |
Alanine Aminotransferase Increased |
3.0% |
Aspartate Aminotransferase Increased |
3.0% |
Erysipelas |
3.0% |
Hepatotoxicity |
3.0% |
Portal Vein Thrombosis |
3.0% |
Rectal Haemorrhage |
3.0% |
Thrombocytopenia |
3.0% |
|